Key Points
- Precigen COO Rutul Shah sold 32,739 shares at an average price of $6.86, worth approximately $224,590, reducing his direct holdings by 6.58% to 465,012 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Precigen reported quarterly revenue of $54.98 million, far above the $27.98 million consensus estimate, and earnings of $0.05 per share versus expectations for a loss of $0.01. Revenue increased more than 6,300% year over year, driven largely by PAPZIMEOS.
- Analyst sentiment remains generally positive: HC Wainwright raised its price target to $18 and maintained a Buy rating, while the stock carries a consensus “Moderate Buy” rating and an average target of $14.50.
Precigen, Inc. (NASDAQ:PGEN - Get Free Report) COO Rutul Shah sold 32,739 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $6.86, for a total value of $224,589.54. Following the completion of the sale, the chief operating officer directly owned 465,012 shares in the company, valued at approximately $3,189,982.32. The trade was a 6.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Precigen Stock Performance
Shares of PGEN opened at $7.23 on Friday. Precigen, Inc. has a 12-month low of $1.70 and a 12-month high of $7.26. The company has a current ratio of 4.58, a quick ratio of 4.12 and a debt-to-equity ratio of 2.15. The company has a market cap of $2.58 billion, a PE ratio of -6.95 and a beta of 1.02. The stock has a 50-day moving average price of $5.23 and a 200-day moving average price of $4.50.
Precigen (NASDAQ:PGEN - Get Free Report) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $0.06. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The business had revenue of $54.98 million for the quarter, compared to the consensus estimate of $27.98 million. Precigen's quarterly revenue was up 6322.7% compared to the same quarter last year. As a group, equities analysts forecast that Precigen, Inc. will post 0.05 earnings per share for the current fiscal year.
Precigen News Roundup
Here are the key news stories impacting Precigen this week:
- Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
- Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
- Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
- Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.
Institutional Investors Weigh In On Precigen
Several hedge funds have recently bought and sold shares of the business. Xponance LLC increased its stake in Precigen by 21.3% during the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 2,496 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company's stock valued at $170,000 after acquiring an additional 2,993 shares in the last quarter. Composition Wealth LLC increased its holdings in shares of Precigen by 16.5% in the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company's stock worth $89,000 after purchasing an additional 3,000 shares in the last quarter. Intech Investment Management LLC raised its stake in shares of Precigen by 5.2% in the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company's stock worth $263,000 after purchasing an additional 3,137 shares during the last quarter. Finally, Cetera Investment Advisers lifted its holdings in shares of Precigen by 0.9% during the first quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company's stock valued at $1,449,000 after purchasing an additional 3,250 shares in the last quarter. Institutional investors own 33.51% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on PGEN shares. Wall Street Zen raised shares of Precigen from a "hold" rating to a "strong-buy" rating in a report on Saturday. Citigroup reiterated an "outperform" rating on shares of Precigen in a research report on Thursday, May 14th. Citizens Jmp boosted their target price on Precigen from $9.00 to $11.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Precigen in a research note on Friday, July 17th. Finally, HC Wainwright lifted their price target on shares of Precigen from $14.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $14.50.
Get Our Latest Analysis on Precigen
Precigen Company Profile
(
Get Free Report)
Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.
The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
